What are the 1-year returns of ITI Pharma and Healthcare Fund Direct-Growth?
ITI Pharma and Healthcare Fund Direct-Growth has delivered a 1-year return of 7.08% as of 16 Jul 2026. During the same period, its benchmark NIFTY Healthcare Total Return Index. returned 15.89%. The fund has underperformed its benchmark over this period.
What are the 3-year returns of ITI Pharma and Healthcare Fund Direct-Growth?
ITI Pharma and Healthcare Fund Direct-Growth has delivered a 3-year CAGR of 21.37% as of 16 Jul 2026. Its benchmark NIFTY Healthcare Total Return Index. returned 46.11% CAGR over the same period. CAGR (Compounded Annual Growth Rate) is the right way to evaluate multi-year mutual fund performance as it smooths out year-to-year volatility.
What are the 5-year returns of ITI Pharma and Healthcare Fund Direct-Growth?
The 5-year CAGR for ITI Pharma and Healthcare Fund Direct-Growth is shown in the Trailing Returns section above.
What are the returns of ITI Pharma and Healthcare Fund Direct-Growth since inception?
Since its launch on 10 Nov 2021, ITI Pharma and Healthcare Fund Direct-Growth has delivered a CAGR of 15.18%. Since-inception returns reflect the fund's full history and give the most complete picture of long-term performance.
How has ITI Pharma and Healthcare Fund Direct-Growth performed vs its category over the long term?
Over the long term, ITI Pharma and Healthcare Fund Direct-Growth has ranked 9 out of 9 funds in the Equity: Sectoral-Pharma category on a 3-year basis, and - on a 5-year basis. Category rank is one of several factors to consider alongside risk metrics and rolling return consistency when evaluating a fund.
What is the Sharpe ratio of ITI Pharma and Healthcare Fund Direct-Growth?
The Sharpe ratio of ITI Pharma and Healthcare Fund Direct-Growth is 0.91 (as of 16 Jul 2026). The Sharpe ratio measures how much return the fund generates per unit of risk (volatility) taken. A Sharpe ratio above 1.0 is generally considered good — the higher the ratio, the better the risk-adjusted return.
What is the alpha of ITI Pharma and Healthcare Fund Direct-Growth?
The 3Y alpha of ITI Pharma and Healthcare Fund Direct-Growth is -2.51% (as of 16 Jul 2026). Alpha measures the excess return generated by the fund over and above its benchmark NIFTY Healthcare Total Return Index., after adjusting for risk. A positive alpha means the fund manager has added value beyond what the market delivered. A negative alpha means the fund has underperformed its benchmark on a risk-adjusted basis.
What is the beta of ITI Pharma and Healthcare Fund Direct-Growth?
The beta of ITI Pharma and Healthcare Fund Direct-Growth is 0.98 (as of 16 Jul 2026). Beta measures how sensitive the fund is to market movements relative to its benchmark NIFTY Healthcare Total Return Index.. A beta of 1 means the fund moves in line with the market. A beta above 1 means it is more volatile than the market; below 1 means it is less volatile. ITI Pharma and Healthcare Fund Direct-Growth's beta of 0.98 indicates it is more defensive than its benchmark.
What are the rolling returns of ITI Pharma and Healthcare Fund Direct-Growth?
The average 1-year and 3-year rolling returns of ITI Pharma and Healthcare Fund Direct-Growth is 20.30% and 22.16% respectively. Rolling returns show the fund's annualized return across every possible 1-year and 3-year investment window, making them a far more reliable measure of consistency than point-to-point returns, which depend heavily on the start and end date chosen.
